Last one was undersubscribed with - options expiring Aug 2011, exercise 15c.
Maybe management have learnt something.
This one oversubscribed with options expiring 2016, exercise 9c.
Higher price for shares but a much, much better deal on options. If they had offered that last time I wonder if the uptake would have been substantially more ?
Anyway, these bucks should see them funded for quite awhile, along with the income they are deriving from the research.
I will be interested to see the figure from Roche - next quarterly perhaps ?
Q. where will these new shares be traded - ASX, Frankfurt ?
(did we get a NASDAQ listing ? (-:)
I never did quite understand where shares came from to trade on the Frankfurt exchange.
Last one was undersubscribed with - options expiring Aug 2011,...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.37 |
Change
0.005(0.37%) |
Mkt cap ! $836.9M | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.44 | $1.34 | $546.6K | 401.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11187 | $1.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.37 | 5000 | 1 |
View Market Depth
| Last trade - 15.23pm 16/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |